Veru GAAP EPS of -$0.05 beats by $0.01, revenue of $3.93M

Stock Information for Veru Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Veru Inc.

Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation
Veru to Participate in the Virtual BTIG Obesity Health Forum
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
Veru Participates in a Virtual Investor KOL Connect Segment
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress
Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8
Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit
Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.